Introduction

Dyspareunia is a common, but little-known, chronic problem, described as persistent or recurring pain that occurs during sexual intercourse.\(^1\) It is a multifactorial pathology that involves psychological, biological and social factors. The incidence of dyspareunia is difficult to determine because women do not usually resort to consultation. The prevalence is around 10% of women of childbearing age and 45% of postmenopausal women.\(^2\) Estrogen deficiency can lead to vaginal atrophy, the symptoms of which include vaginal dryness as well as dyspareunia, burning, and dysuria; urgent urinary symptoms, and recurrent urinary tract infections (UTIs).\(^3\) Dyspareunia can be classified in different ways: depending on the moment in which the pain appeared (primary or secondary), in the situational context (generational or situational) and the one that is most used today in clinical practice is based on its location (superficial or deep). This classification allows us to distinguish between the variable causes of dyspareunia and reduces differential diagnoses.\(^1\) Superficial dyspareunia is defined as pain when attempting vaginal penetration into the introitus, whereas in deep dyspareunia, pain is felt on vaginal penetration. Possible causes are listed in the following Table 1.

Due to this, women generally suffer alterations in their mood and feel distressed by changes in sexual function. Therefore, it is important that the doctor inquire about their sexual health and that the sexual concerns of the women are normalized and universalized.\(^4\) Genitourinary syndrome of menopause (GSM) affects approximately 27% to 84% of postmenopausal women and can significantly affect their health, sexual function, and quality of life.\(^5\) The diagnosis of GSM includes questioning and vaginal examination. Because the majority of women do not report these events, because they attribute it to physiological changes of aging, it is recommended to inquire about these symptoms in all perimenopausal and postmenopausal women including the collection of useful data such as time of onset, duration, levels of associated distress, how it affects their quality of life, their sexual activity and the relationship with their partner. Data was collected by the Vaginal Health: Insights, Views & attitudes (VIVA-LATAM) survey,\(^6\) in which 2509 women from Argentina, Brazil, Chile, Colombia and Mexico between 55 and 65 years old participated. The data showed that generally they had little knowledge about vaginal atrophy. However, the majority of the surveyed population (79%) were aware of the treatment options, mainly lubricating gels and creams (59%). The CLOSER survey\(^7\) considered the impact of vaginal discomfort and its treatment on the self-esteem of postmenopausal women and intimate relationships between postmenopausal women and their partners. The answers revealed that vaginal discomfort had a negative impact on intimate relationships. Vaginal discomfort made the majority of women (58%) avoid intimacy and experience loss

---

**Table 1:** Etiologies of superficial and deep dyspareunia.

<table>
<thead>
<tr>
<th>Dyspareunia</th>
<th>Superficial</th>
<th>Deep</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anal fissures</td>
<td>Adenomyosis</td>
<td></td>
</tr>
<tr>
<td>Hemorrhoids</td>
<td>Endometriosis</td>
<td></td>
</tr>
<tr>
<td>Vaginal atrophy</td>
<td>Vaginal scars</td>
<td></td>
</tr>
<tr>
<td>Vulvodynia</td>
<td>Pelvic adhesions</td>
<td></td>
</tr>
<tr>
<td>Bartholinitis</td>
<td>Interstitial cystitis</td>
<td></td>
</tr>
<tr>
<td>Vulvovaginitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inadequate lubrication</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaginismus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postpartum dyspareunia</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Quick Response Code: [QR Code Image]  
*Corresponding author: Alejandra Belardo, Chief of the Gynecological Endocrinology Section and Chief of the Climacteric Section, Gynecology Department of the Hospital Italiano de Buenos Aires, Hospital Italiano of Buenos Aires University Institute, Argentina

Received: 25 January, 2021  
Published: 16 February, 2021

of libido. On the men’s side, a higher percentage (78%) believed that vaginal discomfort caused their postmenopausal partners to avoid intimacy. Vaginal discomfort also had a negative effect on the self-esteem of postmenopausal women, and almost one third no longer felt sexually attractive and lost confidence in themselves as a sexual partner.

During the vaginal examination a decrease in the volume of the pubic mound, of the labia majora, decreased tissue and pigmentation of the labia minora and prominences (telescopic), and erythema of the urethral meatus can be observed. The proposal of incorporating sexuality into clinical practice provides strategies for the identification, assessment, and/or referral to a specialist physician for sexual health problems. The treatment of dyspareunia is individualized and should include a shared decision-making approach, the main objective being to alleviate symptoms. First-line treatment is based on non-hormonal vaginal and vulvar lubricants with sexual activity (recommendation A) and vaginal moisturizers of prolonged action. However, there are few studies on the efficacy of these over-the-counter products in the population. The use of pharmacological treatments can provide greater benefits and is indicated when non-hormonal therapy has not been effective and symptoms are severe. These include local hormonal therapy (low-dose vaginal estrogens, dehydroepiandrosterone vaginal) and selective estrogen receptor modulators (SERMs) such as oral ospemifene.

Local estrogen therapy (TEL) causes improvement in symptoms and restores vaginal physiology. All estrogens are effective and safe. TEL should be individualized, given once daily for two weeks and then three, two, or once weekly. It can be prescribed with tablets, ointments, pessaries, creams or vaginal rings containing estradiol, estril, estrone, or conjugated estrogens with equal efficacy. The products vary in dosage and formulation, compared to creams, 17β-estradiol 0.01% (0.1mg active ingredient/g) can be used with an initial dose of 0.5-1g for 2 weeks, conjugated equine estrogens (0.625mg active ingredient/g) with a starting dose of 0.5-1g for 2 weeks or 0.1% estrone (1mg active ingredient/g) with a dose of 0.5-4g planned for short-term use. Regarding vaginal inserts, estradiol 17β inserts 4-10g can be used for 2 weeks or estradiol hemihydrate tablets 10g for 2 weeks. Intravaginal Dehydroepiandrosterone (DHEA) 5% (6.5mg) is used for postmenopausal women with moderate to severe dyspareunia caused by vulvovaginal atrophy.

Its most common adverse effect is vaginal discharge, and it is recommended for use every night for approximately 3 months. Another of the drugs used is promestriene, whose advantage is that vaginal discomfort caused their postmenopausal partners to avoid intimacy. Vaginal discomfort also had a negative effect on the self-esteem of postmenopausal women, and almost one third no longer felt sexually attractive and lost confidence in themselves as a sexual partner.

During the vaginal examination a decrease in the volume of the pubic mound, of the labia majora, decreased tissue and pigmentation of the labia minora and prominences (telescopic), and erythema of the urethral meatus can be observed. The proposal of incorporating sexuality into clinical practice provides strategies for the identification, assessment, and/or referral to a specialist physician for sexual health problems. The treatment of dyspareunia is individualized and should include a shared decision-making approach, the main objective being to alleviate symptoms. First-line treatment is based on non-hormonal vaginal and vulvar lubricants with sexual activity (recommendation A) and vaginal moisturizers of prolonged action. However, there are few studies on the efficacy of these over-the-counter products in the population. The use of pharmacological treatments can provide greater benefits and is indicated when non-hormonal therapy has not been effective and symptoms are severe. These include local hormonal therapy (low-dose vaginal estrogens, dehydroepiandrosterone vaginal) and selective estrogen receptor modulators (SERMs) such as oral ospemifene.

Local estrogen therapy (TEL) causes improvement in symptoms and restores vaginal physiology. All estrogens are effective and safe. TEL should be individualized, given once daily for two weeks and then three, two, or once weekly. It can be prescribed with tablets, ointments, pessaries, creams or vaginal rings containing estradiol, estril, estrone, or conjugated estrogens with equal efficacy. The products vary in dosage and formulation, compared to creams, 17β-estradiol 0.01% (0.1mg active ingredient/g) can be used with an initial dose of 0.5-1g for 2 weeks, conjugated equine estrogens (0.625mg active ingredient/g) with a starting dose of 0.5-1g for 2 weeks or 0.1% estrone (1mg active ingredient/g) with a dose of 0.5-4g planned for short-term use. Regarding vaginal inserts, estradiol 17β inserts 4-10g can be used for 2 weeks or estradiol hemihydrate tablets 10g for 2 weeks. Intravaginal Dehydroepiandrosterone (DHEA) 5% (6.5mg) is used for postmenopausal women with moderate to severe dyspareunia caused by vulvovaginal atrophy.

Its most common adverse effect is vaginal discharge, and it is recommended for use every night for approximately 3 months. Another of the drugs used is promestriene, whose advantage is that vaginal discomfort caused their postmenopausal partners to avoid intimacy. Vaginal discomfort also had a negative effect on the self-esteem of postmenopausal women, and almost one third no longer felt sexually attractive and lost confidence in themselves as a sexual partner.